Filiz İZCİ, Murat YALÇIN, Sumeyye Yasemin Kurtulus CALLİ, Yagmur SEVER, Rabia BİLİCİ

Aripiprazole Augmentation of Clomipramine Therapy in Treatment-Resistant

: Vaka serisi Obsesif-kompulsif bozukluk (OKB) yineleyen, istenmeyen düşünceler ve törensel davranışlarla giden, belirgin sıkıntı ve işlev kaybına neden olan kronik bir hastalıktır. Yapılan çalışmalarda OKB nöropatogenezinde serotonerjik ve dopaminerjik mekanizmaların rol oynadığına ilişkin çeşitli kanıtlar gösterilmiştir. Tedavisinde ilk tercih ilaç olarak Seçici Serotonin Geri Alım İnhibitörleri (SSGİ) kabul edilmektedir, ancak buna karşın SSGİ ile tedavi edilen hastaların yaklaşık %40-60'ında tedavi direnci görülebilmektedir. Tedaviye dirençli OKB'de antidepresanların atipik antipsikotiklerle augmentasyonu önemli bir tedavi seçeneğidir. Biz de bu yazımızda; tedaviye dirençli 5 OKB hastasının klomipramin tedavisine aripiprazolün 10-30mg/gün dozlarının eklenmesiyle tedavide olumlu yanıtlar elde ettiğimiz olgularını sunmayı amaçladık

Obsessive-compulsive disorder (OCD) is a chronic disorder characterized by recurrent intrusive thoughts and repetitive rituals, causing significant distress and functional loss. Studies show evidence about serotonergic and dopaminergic mechanisms in neuropathogenesis of OCD. Selective serotonin re-uptake inhibitors (SSRI) are considered first line treatment in OCDs, but treatment resistance may occur in 40-60% of cases treated with SSRIs. Augmentation of antidepressants with atypical antipsychotics is an important treatment option in treatment-resistant patients with OCD. In this article, we aimed to present five OCD cases with treatment-resistance in which we obtained good outcomes, with addition of aripiprazole 10-30mg per day to clomipramine therapy

PDF

___

Arumugham SS, Reddy JY. Augmentation strategies in obsessive- compulsive disorder. Expert Rev Neurother 2013; 13:1-17. CrossRef]

Ozcubukcuoglu A, Cetin M, Semiz UB. Resistance and biological treatment algorithm for treatment of obsessive-compulsive disorder. Bulletin of Clinical Psychopharmacology 1995; 5:29-38. (Turkish)

Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006-1011. [CrossRef]

Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann R, Hill CL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry ; 46:1012-1016. [CrossRef]

Ravi Kishore V, Samar R, Janardhan Reddy YC, Chandrasekhar CR, Thennarasu K. Clinical characteristics and treatment response in poor and good insight obsessive-compulsive disorder. Eur Psychiatry 2004; 19:202-208. [CrossRef]

Shetti CN, Reddy YC, Kandavel T, Kashyap K, Singisetti S, Hiremath S, Siddequehusen MU, Raghunandanan S. Clinical predictors of drug nonresponse in obsessive-compulsive disorder. J Clin Psychiatry 2005; 66:1517-1523. [CrossRef]

Erzegovesi S, Cavallini MC, Cavadeni P, Diaferia G, Locatelli M, Bellodi L. Clinical predictors of drug response in obsessive- compulsive disorder. J Clin Psychopharmacol 2001; 21:488-492. CrossRef]

Jenike MA, Baer L, Minichiello WE, Schwartz CE, Carey RJ Jr. Concomittant obsessive compulsive disorder ans schizotypal personality disorder. Am J Psychiatry 1986; 143:530-532. CrossRef] Name of Author

Follow up of the case F.I., S.Y.K.C., Y.S. Literature review F.I., Y.S., R.B., M.Y., S.Y.K.C. Manuscript writing F.I., Y.S., R.B., M.Y., S.Y.K.C. Manuscript review and revisation F.I., M.Y., R.B.